Description of the medicine: Idarubicin (Idarubicin)
(7S-cis) -9-Acetyl-7 - [(3-amino-2,3,6-trideoxy-α-L-lyxohexypyranosyl) oxy] -7,8,9,10-tetrahydro-6,9,11 -trioxy-5,12-naphthacenedione.
Synonym: Zavedos, Zavedos.
The structure is close to rubomycin (daunorubicin).
Produced in the form of hydrochloride.
When ingestion is rapidly absorbed into the digestive tract, bioavailability is 18-39%, C max is 2-4 h, T S is 10-35 h; In cells it turns into idarubicinol, which retains antitumor activity, is excreted by the kidneys.
Applied with lymphomas, acute myeloblastic leukemia and non-lymphocytic leukemia, lung cancer.
Assign inside and intravenously.
Intravenous adults are administered 12 mg / m 2 , children 10 mg / m 2 daily for 3 days every 3-4 weeks.
Inside appoint a dose of 30 mg / m 2 (in combination with other drugs - 15 mg / m 2 ) for 3 days every 3 weeks.
Possible side effects: granulocytopenia, thrombocytopenia, anemia, nausea, vomiting, stomatitis, abnormal liver function, alopecia, cardiotoxic effects (arrhythmias, heart failure), allergic reactions, sclerotherapy of veins after intravenous infusions).
Contraindications: heart disease, myelosuppression, dysfunction of the liver and (or) kidneys, infectious diseases, pregnancy, breast-feeding.
Forms of release: capsules to 0,005; 0.01 and 0.025 g (5, 10 and 25 mg); Powder for injection solutions in bottles of 0.005 g (5 mg).
Storage: List A.